Connect with us
Between the high cost and testing hurdles, molnupiravir may not be the “game changer” against COVID. Read More
What motivation science has to say about goodbyes. Plus, GE’s $1.45 billion acquisition and monoclonal antibody bottleneck. Read More
Africa desperately needs COVID vaccines, and local production deals are starting to appear. Read More
We’re starting to learn more and more about how COVID vaccines interact with variants. But we’ll still need vigilance and months of more data. Read More
Recent Comments